Examining Persistence in Smokers With Schizophrenia
Primary Purpose
Smoking Cessation, Schizophrenia, Schizo Affective Disorder
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
counseling
Sponsored by
About this trial
This is an interventional treatment trial for Smoking Cessation
Eligibility Criteria
Inclusion Criteria:
- Must be between 18 - 64 years old
- Must indicate commitment to quitting smoking in the next 30 days
- Must smoke at least 5 cigarettes per day for past 6-months
- Expired breath carbon monoxide (CO) > 5 to ensure daily cigarette use
- Must score < 8 (or <7 for women) on the Alcohol Use Disorders Identification Test
- Must score less than 3 on the 6-month Drug Abuse Screening Test-10
- Must provide a negative urine drug screen for cannabis, cocaine, opiates, or
- methamphetamine (Note: Participants with a positive screen for opiates may
- participate with proof of prescription for opiates.)
- Must have a diagnosis of Schizophrenia or Schizoaffective Disorder on Structured Clinical Interview
- Psychiatric illness must be stable, as indicated by no hospitalizations in previous 8 weeks, and a stable psychotropic medication regimen including a stable antipsychotic dose for 8 weeks
Exclusion Criteria:
- Must not be currently receiving tobacco dependence treatment counseling
- Must not currently be taking varenicline (Chantix)
- Must not be taking bupropion (Zyban/Wellbutrin) to quit smoking
- Must not be taking any nicotine preparations (gum, lozenge, patch, spray, inhaler) daily over the last 10 days.
- Must not report unstable angina pectoris, myocardial infarction, or significant cardiac arrhythmia (including atrial fibrillation) in the past 90 days
- Must not be pregnant, breastfeeding, or planning on becoming pregnant in the next 4-months. Women who can become pregnant may be included if using effective birth control
- Must not have pending legal matters with potential to result in jail time
- Must not be planning on moving outside local area in next 3-months
Sites / Locations
- Rutgers Robert Wood Johnson Medical School
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Persistence Targeted Smoking Cessation
Arm Description
8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
Outcomes
Primary Outcome Measures
Task Persistence - Mirror Tracing
Number of seconds persisting on a computerized mirror tracing task (Higher number of seconds = greater persistence)
Task Persistence - Sustained Divided Attention Task
Seconds persisting on Sustained Divided Attention Task (Higher number of seconds = greater persistence)
Task Persistence - Breath-holding
Number of seconds persisting on a breath-holding endurance task (Higher number of seconds = greater persistence)
Task Persistence -Temperament and Character Inventory-Persistence Scale (TCI-P)
Score on Temperament and Character Inventory-Persistence Scale (TCI-P) (Higher score = greater persistence)
Task Persistence - 2-item Task Persistence Measure
Score on 2-item Task Persistence Measure (Higher score = greater persistence)
Task Persistence - Distress Tolerance Scale (DTS)
Score on Distress Tolerance Scale (DTS) (Higher score = greater persistence)
Task Persistence - Thoughts About Smoking Questionnaire
Score on the Thoughts About Smoking Questionnaire (Higher score = less persistence)
Self-reported ratings of ease of understanding and helpfulness of counseling
percentage of participants who rate the intervention as "easy to understand" and "helpful"
Secondary Outcome Measures
Full Information
NCT ID
NCT03346291
First Posted
November 3, 2017
Last Updated
January 15, 2019
Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Institute on Drug Abuse (NIDA)
1. Study Identification
Unique Protocol Identification Number
NCT03346291
Brief Title
Examining Persistence in Smokers With Schizophrenia
Official Title
Examining Persistence in Smokers With Schizophrenia
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
January 2017 (Actual)
Primary Completion Date
June 13, 2018 (Actual)
Study Completion Date
June 13, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Institute on Drug Abuse (NIDA)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
All participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks). They will complete assessment measures commonly used in smoking cessation studies. We hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.
Detailed Description
This study is a non-randomized trial of a new psychosocial treatment for smoking cessation (for smokers with schizophrenia) that is based on cognitive behavioral therapy for smoking cessation - a commonly used approach. Participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks). They will complete assessment measures commonly used in smoking cessation studies. We hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smoking Cessation, Schizophrenia, Schizo Affective Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
27 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Persistence Targeted Smoking Cessation
Arm Type
Experimental
Arm Description
8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
Intervention Type
Behavioral
Intervention Name(s)
counseling
Intervention Description
individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
Primary Outcome Measure Information:
Title
Task Persistence - Mirror Tracing
Description
Number of seconds persisting on a computerized mirror tracing task (Higher number of seconds = greater persistence)
Time Frame
Through end-of-treatment - approximately 8 weeks after baseline
Title
Task Persistence - Sustained Divided Attention Task
Description
Seconds persisting on Sustained Divided Attention Task (Higher number of seconds = greater persistence)
Time Frame
Through end-of-treatment - approximately 8 weeks after baseline
Title
Task Persistence - Breath-holding
Description
Number of seconds persisting on a breath-holding endurance task (Higher number of seconds = greater persistence)
Time Frame
Through end-of-treatment - approximately 8 weeks after baseline
Title
Task Persistence -Temperament and Character Inventory-Persistence Scale (TCI-P)
Description
Score on Temperament and Character Inventory-Persistence Scale (TCI-P) (Higher score = greater persistence)
Time Frame
Through end-of-treatment - approximately 8 weeks after baseline
Title
Task Persistence - 2-item Task Persistence Measure
Description
Score on 2-item Task Persistence Measure (Higher score = greater persistence)
Time Frame
Through end-of-treatment - approximately 8 weeks after baseline
Title
Task Persistence - Distress Tolerance Scale (DTS)
Description
Score on Distress Tolerance Scale (DTS) (Higher score = greater persistence)
Time Frame
Through end-of-treatment - approximately 8 weeks after baseline
Title
Task Persistence - Thoughts About Smoking Questionnaire
Description
Score on the Thoughts About Smoking Questionnaire (Higher score = less persistence)
Time Frame
Through end-of-treatment - approximately 8 weeks after baseline
Title
Self-reported ratings of ease of understanding and helpfulness of counseling
Description
percentage of participants who rate the intervention as "easy to understand" and "helpful"
Time Frame
Through end-of-treatment - approximately 8 weeks after baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must be between 18 - 64 years old
Must indicate commitment to quitting smoking in the next 30 days
Must smoke at least 5 cigarettes per day for past 6-months
Expired breath carbon monoxide (CO) > 5 to ensure daily cigarette use
Must score < 8 (or <7 for women) on the Alcohol Use Disorders Identification Test
Must score less than 3 on the 6-month Drug Abuse Screening Test-10
Must provide a negative urine drug screen for cannabis, cocaine, opiates, or
methamphetamine (Note: Participants with a positive screen for opiates may
participate with proof of prescription for opiates.)
Must have a diagnosis of Schizophrenia or Schizoaffective Disorder on Structured Clinical Interview
Psychiatric illness must be stable, as indicated by no hospitalizations in previous 8 weeks, and a stable psychotropic medication regimen including a stable antipsychotic dose for 8 weeks
Exclusion Criteria:
Must not be currently receiving tobacco dependence treatment counseling
Must not currently be taking varenicline (Chantix)
Must not be taking bupropion (Zyban/Wellbutrin) to quit smoking
Must not be taking any nicotine preparations (gum, lozenge, patch, spray, inhaler) daily over the last 10 days.
Must not report unstable angina pectoris, myocardial infarction, or significant cardiac arrhythmia (including atrial fibrillation) in the past 90 days
Must not be pregnant, breastfeeding, or planning on becoming pregnant in the next 4-months. Women who can become pregnant may be included if using effective birth control
Must not have pending legal matters with potential to result in jail time
Must not be planning on moving outside local area in next 3-months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc L Steinberg, Ph.D.
Organizational Affiliation
Rutgers, The State University of New Jersey
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rutgers Robert Wood Johnson Medical School
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08901
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Examining Persistence in Smokers With Schizophrenia
We'll reach out to this number within 24 hrs